regeneron_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 22, 2011 (August 22, 2011)

     
  REGENERON PHARMACEUTICALS, INC.  
  (Exact Name of Registrant as Specified in Charter)  
     

New York       000-19034       13-3444607
(State or other jurisdiction of   (Commission File No.)   (IRS Employer Identification No.)
Incorporation)        

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)
     
  (914) 347-7000  
  (Registrant's telephone number, including area code)  
     

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 7.01 Regulation FD Disclosure.
 
     On August 22, 2011, at the American Society of Retina Specialists meeting in Boston, Massachusetts, data from the Phase 3 COPERNICUS Study of the safety, efficacy, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in patients with macular edema secondary to central retinal vein occlusion will be presented by W. Lloyd Clark, M.D. A copy of the slides that will be presented is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1       Presentation entitled VEGF Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study
 
 

SIGNATURES
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 22, 2011       REGENERON PHARMACEUTICALS, INC.
     
     
    By:  /s/ Murray A. Goldberg
    Name: Murray A. Goldberg
    Title: Senior Vice President, Finance and
    Administration, Chief Financial Officer, Treasurer,
    and Assistant Secretary

 

Exhibit Index
 
Number       Description
99.1   Presentation entitled VEGF Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study